CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-09 | Boyd Peter E. See Remark | Grant or award | +100,000 | 159,532 | ||
| 2023-03-09 | Marshall Ken W. SVP, Chief Commercial Officer | Grant or award | +150,000 | 150,000 | ||
| 2023-03-09 | Jung Cassie SVP, Operations | Grant or award | +110,000 | 146,747 | ||
| 2023-03-09 | Schobel Alexander Mark Chief Innovation/Tech Officer | Grant or award | +100,000 | 982,871 | ||
| 2023-03-09 | Barber Daniel President and CEO | Grant or award | +447,000 | 640,702 | ||
| 2023-03-09 | BRAENDER LORI J SVP, General Counsel | Grant or award | +150,000 | 188,761 | ||
| 2023-03-09 | Wargacki Stephen SVP, Research & Development | Grant or award | +135,000 | 161,956 | ||
| 2023-03-09 | TOTH A ERNEST JR SVP, Chief Financial Officer | Grant or award | +140,000 | 140,000 | ||
| 2022-11-04 | Boyd Peter E. SVP-Bus. Process & Info. Tech. | Grant or award · Non-Qualified Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2022-11-04 | BRAENDER LORI J SVP, General Counsel | Grant or award · Non-Qualified Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-11-04 | Marshall Ken W. SVP, Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-11-04 | Schobel Alexander Mark Chief Innovation/Tech Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-11-04 | TOTH A ERNEST JR SVP, Chief Financial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-09-06 | Truitt Kenneth Chief Medical Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2022-08-16 | MORRIS TIMOTHY E Director | Grant or award · Non-Qualified Stock Option (right to buy) | +28,500 | 28,500 | ||
| 2022-08-05 | Barber Daniel President and CEO | Grant or award · Non-Qualified Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2022-06-22 | Cochran John Director | Grant or award · Stock Option (Right to Purchase) | +25,000 | 25,000 | ||
| 2022-06-22 | BROWN GREGORY B Director | Grant or award · Stock Option (Right to Purchase) | +25,000 | 25,000 | ||
| 2022-06-22 | Taglietti Marco Director | Grant or award · Stock Option (Right to Purchase) | +25,000 | 25,000 | ||
| 2022-06-22 | Krop Julie Director | Grant or award · Stock Option (Right to Purchase) | +25,000 | 25,000 |
Page 11 of 24 · 462 trades